| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.3 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.3 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.3 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |